Table 4.
Outcomes for the exposed group by type of cancer, based on a one year lag period
| Cancer type (ICD-10 code)* | Observed no of cancers | IRR (95% CI; exposed v unexposed)† | No of excess cancers† | EIR (95% CI) per 100 000 person years† |
|---|---|---|---|---|
| All solid cancers (C00-80) | 2507 | 1.25 (1.20 to 1.31) | 503.2 | 7.76 (6.24 to 9.27) |
| Mouth and pharynx (C00-14) | 87 | 1.08 (0.87 to 1.35) | 6.3 | 0.10 (−0.18 to 0.38) |
| Digestive organs (C15-26) | 149 | 1.29 (1.09 to 1.52) | 32.8 | 0.51 (0.14 to 0.87) |
| Respiratory organs (C30-39) | 48 | 1.31 (0.97 to 1.76) | 11.5 | 0.18 (−0.03 to 0.39) |
| Bone (C40-41) | 72 | 1.15 (0.91 to 1.47) | 9.7 | 0.15 (−0.11 to 0.41) |
| Melanoma (C43-44) | 809 | 1.12 (1.04 to 1.20) | 86.8 | 1.34 (0.48 to 2.20) |
| Soft tissue (C45-49) | 119 | 1.78 (1.47 to 2.16) | 51.7 | 0.80 (0.47 to 1.13) |
| Breast (C50) | 145 | 0.99 (0.83 to 1.17) | −1.8 | −0.03 (−0.39 to 0.34) |
| Female genital organs (C51-58) | 181 | 1.28 (1.10 to 1.49) | 40.1 | 0.62 (0.21 to 1.02) |
| Male genital organs (C60-63) | 275 | 1.08 (0.95 to 1.22) | 19.9 | 0.31 (−0.19 to 0.81) |
| Urinary tract (C64-C68) | 51 | 1.33 (1.00 to 1.78) | 13.3 | 0.21 (−0.01 to 0.42) |
| Brain (C69-72) | 283 | 2.13 (1.88 to 2.41) | 147.3 | 2.27 (1.76 to 2.78) |
| Brain after brain CT scan | 210 | 2.44 (2.12 to 2.81) | 122.7 | 2.97 (2.28 to 3.66) |
| Brain after other CT scan | 73 | 1.51 (1.19 to 1.91) | 24.6 | 1.05 (0.33 to 1.76) |
| Thyroid (C73-75) | 258 | 1.40 (1.23 to 1.59) | 71.4 | 1.10 (0.62 to 1.59) |
| Ill defined and unspecified sites (C76-80) | 30 | 1.85 (1.27 to 2.71) | 14.0 | 0.22 (0.05 to 0.38) |
| All lymphoid and haematopoietic cancers (C81-96, D45-46, D47.1, D47.3) | 643 | 1.19 (1.10 to 1.29) | 105.3 | 1.62 (0.86 to 2.39) |
| Hodgkin’s lymphoma (C81) | 228 | 1.15 (1.01 to 1.32) | 30.4 | 0.47 (0.01 to 0.92) |
| Other lymphomas (C82-83) | 104 | 1.01 (0.82 to 1.23) | 0.2 | 0.00 (−0.30 to 0.31) |
| Other lymphoid cancers (C84-90) | 65 | 1.70 (1.31 to 2.20) | 26.8 | 0.41 (0.17 to 0.66) |
| Leukaemias and myelodysplasias (C91-96, D45-46, D47.1, D47.3) | 246 | 1.23 (1.08 to 1.41) | 47.8 | 0.74 (0.26 to 1.21) |
| Leukaemias (C91-96) | 211 | 1.19 (1.03 to 1.37) | 34.3 | 0.53 (0.09 to 0.97) |
| Lymphoid leukaemia (C91) | 84 | 0.96 (0.77 to 1.20) | −2.1 | −0.03 (−0.31 to 0.24) |
| Myeloid and other leukaemias (C92-96) | 127 | 1.41 (1.18 to 1.70) | 36.4 | 0.56 (0.22 to 0.90) |
| Myelodysplasia (D45-D46, D47.1, D47.3) | 35 | 1.60 (1.13 to 2.27) | 13.5 | 0.21 (0.03 to 0.39) |
| All cancers | 3150 | 1.24 (1.20 to 1.29) | 608.4 | 9.38 (7.68 to 11.08) |
| All solid cancers, except brain cancer after brain CT | 2297 | 1.20 (1.15 to 1.25) | 380.4 | 5.86 (4.35 to 7.38) |
| All cancers, except brain cancer after brain CT | 2940 | 1.20 (1.15 to 1.24) | 485.7 | 7.49 (5.79 to 9.18) |
Web tables A and B show results based on lag periods of five and 10 years, respectively. IRR=incidence rate ratio, exposed v unexposed; EIR=absolute excess incidence rate compared with rates in unexposed group.
*ICD codes most accurately reflect the cancer types in tables 4-9. The names used referred to the commonest cancer types in each rubric (for example, rubric C69-72 referred to eye cancer and other cancers of the central nervous system as well as brain cancer); rubric C73-75 referred to thyroid cancer and other endocrine cancers). C97 was not included in this table, because it was not used for cancer incidence registrations.
†IRR, EIR, and number of excess cancers calculated after stratification for age, sex, and year of birth.